Journals / MN Oftalmoloji / 2006 / Cilt: 13 - Sayı: 1

Effects of anti-glaucoma drugs on corneal endothelial cell count

Anti-glokomatöz ilaçların kornea endotel hücre sayısı üzerine etkileri

Pages
31–33
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: There was no a significant decrease in the corneal endothelial cell count in eyes that ha­ve been treated with timolol maleat 0.50%, travoprost 0.004%, and brinzolamide 1%.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To investigate the effects of antiglaucoma eyedrops on corneal endothelial cell count u­sing specular microscope.
📊
Key Findings & Data:Mareial and Methods: This study consisted of 123 eyes of 64 glaucoma patients.
💡
Conclusion & Impact:Conclusion: There was no a significant decrease in the corneal endothelial cell count in eyes that ha­ve been treated with timolol maleat 0.50%, travoprost 0.004%, and brinzolamide 1%.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Glokom · İleriye dönük çalışma · Timolol

Abstract

Purpose: To investigate the effects of antiglaucoma eyedrops on corneal endothelial cell count u­sing specular microscope. Mareial and Methods: This study consisted of 123 eyes of 64 glaucoma patients. The patients we­re di­vi­ded into three groups (groupA: timolol maleat 0.50%, groupB: travoprost 0.004%, groupC: brin­zo­la­mi­de 1%) and underwent a complete ophthalmic examination. The mean endothelial cell counts we­re e­va­luated by specular microscopy before treatment and after 1, 4, 12, and 24 weeks of treatment. Results: In all three treatment groups, after treatment, no difference in the mean endothelial cell counts was observed that before treatment. There was no significant difference in the mean endothelial cell counts among 3 groups before and after treatment (p>0.05). Conclusion: There was no a significant decrease in the corneal endothelial cell count in eyes that ha­ve been treated with timolol maleat 0.50%, travoprost 0.004%, and brinzolamide 1%.

Özet

Amaç: Topikal glokom ilaçlarının kornea endotel hücre sayısı üzerine olan etkilerini speküler mik­ros­kop (SM) ile değerlendirmek. Gereç ve Yöntem: Çalışmaya 64 glokom hastasının 123 gözü alındı. Aldıkları ilaçlara göre olgular 3 gruba ayrıldı (Grup A: timolol maleat %0.50, grup B: travoprost %0.004, grup C:brinzolamid %1). Has­talara tam bir oftalmolojik muayene yapıldı ve temas etmeyen speküler mikroskopi ile mm² deki en­do­tel hücre yoğunluğu tedavi öncesi ve sonrası değerlendirildi. Muayeneler birinci, dördüncü, 12. ve 24. haftalarda tekrarlandı. Bulgular: Ortalama endotel hücre sayısı, her üç grupta tedavi öncesi ve tedavi sonrası ve hasta grup­ları arasında istatistiksel açıdan anlamlı bir fark göstermedi (p>0.05). Sonuç: Timolol maleat %0.50, travoprost 0%.004 ve brinzolamid % 1 ile tedavi edilen gözlerde en­do­tel hücre sayısında anlamlı bir azalma yoktu.

🔖

Cite This Article

GEREM, F., TURAÇLI, M. E., TEKELİ, O. (2006). Effects of anti-glaucoma drugs on corneal endothelial cell count. MN Oftalmoloji, Cilt: 13 - Sayı: 1, 31–33. https://ajindex.com/articles/296011

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Matsuda M, Ishii Y, Awata T, Fukuda M. The effect of long-term topical administration of commercial beta- blockers on the rat corneal endothelium. Int Ophthalmol 1989
  2. 13 (1-2):67-73. 2.Lass JH, Eriksson GL, Osterling L, et al. Comparison of the effects of latanoprost, fixed combination latanoprost-timolol, and timolol. Ophthalmology 2001
  3. Korey M, Gieser D, Kass MA, et al. Central corneal en-dothelial cell density and central corneal thickness in ocular hypertension and open-angle glaucoma. Am J Ophthalmol 1982
  4. Knorr HL, Handel A, Naumann GO. Morphometric and qualitative changes in corneal endothelium in primary chronic open angle glaucoma. Fortschr Ophthalmol 1991
  5. Gagnon MM, Boisjoly HM, Brunette I, et al. Corneal en-dothelial cell density in glaucoma. Cornea 1997
  6. Srinivas SP, Ong A, Zhai C, Bonanno J. Inhibition of carbonic anhydrase activity in cultured bovine corneal endothelial cells by dorzolamide. Invest Ophthalmol Vis Sci 2002
  7. . 7.Wilkerson M, Cyrlin M, Lippa EA, et al. Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor. Arch Ophthalmol 1993
  8. Uva MG, Russo V, Longo A, et al. 2% dorzolamide and cornea: An ultrabiomicroscopic study. Acta Ophthalmol Scand 1997
  9. 23 24. 9.Konowal A, Morrison JC, Brown SV, et al. Irreversible corneal decompensation in patients treated with topical dorzolamide. Am J Ophthalmol 1999
  10. Travatan [package insert]. Fort Worth, TX: Alcon Labs, 2001